(Q38152899)

29 August 2017

title

Novel cancer therapies: treatments driven by tumour biology (English)

1 reference

29 August 2017

Ramya Ramaswami

1

1 reference

29 August 2017

Victoria Harding

series ordinal

2

1 reference

29 August 2017

Thomas Newsom-Davis

series ordinal

3

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 November 2013

1 reference

Postgraduate Medical Journal

29 August 2017

published in

1 reference

29 August 2017

volume

89

1 reference

29 August 2017

issue

1057

1 reference

29 August 2017

page(s)

652-658

1 reference

Hallmarks of Cancer: The Next Generation

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

An overview of cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Integrating molecular diagnostics into anticancer drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Methodological and practical challenges for personalized cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

The BATTLE trial: personalizing therapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPOSTGRADMEDJ-2012-131533

10.1136/POSTGRADMEDJ-2012-131533

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference